raj0511 Posted - 6 hours ago

$BGNE

insiderbuyingselling Posted - 4 days ago

$BGNE new insider selling: 50000 shares. http://insiderbuyingselling.com/?t=BGNE

DonCorleone77 Posted - 5 days ago

$LLY $VRTX $BGNE $AVBP $DNTH Drugmakers look to alternative suppliers after draft U.S. legislation, FT says Western pharmaceutical companies are looking into alternative suppliers after the release of a draft U.S. legislation that is seeking to restrict a Chinese drug developer and manufacturer over national security concerns, Oliver Barnes, Ian Johnston, and Eleanor Olcott of The Financial Times says. The Biosecure Act would prohibit U.S. companies receiving federal grant money from working with four Chinese biotech companies, including WuXi AppTec and WuXi Biologics. Eli-Lilly (LLY), Vertex Pharmaceuticals (VRTX), and BeiGene (BGNE), among others, have been discussing with rival contract manufacturers to diversify production, several people familiar with discussions said. ArriVent BioPharma (AVBP) and Dianthus Therapeutics (DNTH) are also exploring alternative manufacturing options.

MUNEMAKER Posted - 1 week ago

$BGNE Is the gd paint dry yet? Lol

zhima Posted - 1 week ago

$BGNE

erevnon Posted - 03/27/24

Bernstein maintains BeiGene $BGNE at Market Perform and lowers the price target from $196 to https://marketsblock.com/stock-upgrades-and-downgrades/

TickerDD_com Posted - 03/21/24

From 3/13/2024, looking back across 22 Month-Ends for BGNE, Percentage Change of Average Monthly Price had More Positives (59%) while Percentage Change of Average Monthly Volume had All Positives (100%) $BGNE #BGNE #BGNEStock #TickerDD https://www.youtube.com/watch?v=yQ0_I2NTcW4

SierraNevada Posted - 03/19/24

$BGNE The Top 25 Biotechnology Companies of 2024 | The Healthcare Technology Report. https://thehealthcaretechnologyreport.com/the-top-25-biotechnology-companies-of-2024/

DonCorleone77 Posted - 1 month ago

$BGNE BeiGene receives FDA approval for Tevimbra BeiGene announced that the U.S. Food and Drug Administration has approved TEVIMBRA as monotherapy for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. TEVIMBRA will be available in the U.S. in the second half of 2024. "Today's FDA approval of TEVIMBRA for patients with ESCC who have previously received chemotherapy, along with its ongoing review of our BLA for first-line ESCC patients, represents a significant step in our commitment to bringing this therapy to more patients around the world," said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeiGene. "As BeiGene's first drug candidate produced through our immuno-oncology program and second approved medicine in the U.S., TEVIMBRA is poised to be a critical pillar of our solid tumor development program...."

Stock_Titan Posted - 1 month ago

$BGNE BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy https://www.stocktitan.net/news/BGNE/bei-gene-receives-fda-approval-for-tevimbra-r-for-the-treatment-of-kiy5e4jvokih.html

Stock_Titan Posted - 1 month ago

$BGNE Pi Health Raises Over $30M in Series A to Revolutionize Cancer Care and Clinical Trials https://www.stocktitan.net/news/BGNE/pi-health-raises-over-30m-in-series-a-to-revolutionize-cancer-care-2xtk66rzxvxo.html

briefingcom Posted - 1 month ago

$BGNE: First doses of BRUKINSA provided to patients with Chronic Lymphocytic Leukemia in low- and middle-income countries under collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation

GetVector Posted - 1 month ago

Vector Intelligence (VI) is an algorithm designed to predict potential outsized intraday moves. VI will select up to 4 stocks per day. Today's VI stocks: $BGNE, $SKIN.

Pika_Capital Posted - 1 month ago

$BGNE pre market looks good. Not sure what's going on. Time to clear $200. This is way too cheap

Stock_Titan Posted - 1 month ago

$BGNE First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation https://www.stocktitan.net/news/BGNE/first-doses-of-brukinsa-r-provided-to-patients-with-chronic-5gz6gh0gkyf6.html

MUNEMAKER Posted - 1 month ago

$BGNE This shit is bipolar

Stock_Titan Posted - 1 month ago

$BGNE BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma https://www.stocktitan.net/news/BGNE/bei-gene-announces-fda-accelerated-approval-of-brukinsa-for-the-148r53stqeej.html

TradeHawk Posted - 1 month ago

$BGNE FDA grants accelerated approval to zanubrutinib for relapsed or refractory follicular lymphoma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zanubrutinib-relapsed-or-refractory-follicular-lymphoma

Stock_Titan Posted - 1 month ago

$BGNE BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024 https://www.stocktitan.net/news/BGNE/bei-gene-to-present-clinical-and-preclinical-data-from-broad-ndu8xy7gat4e.html

coolio1982 Posted - 1 month ago

$BGNE why does this fluctuate so much?

Aigner_Andreas Posted - 02/29/24

TD SELL $BGNE at 165.65, Supp 141.80 Resis 179.69 R27 HiLo 19% T1Y 267 buy 1.9 DIV N/A #BeiGene Lt #stocks #trading #finance #market

Stock_Titan Posted - 02/29/24

$BGNE BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia https://www.stocktitan.net/news/BGNE/bei-gene-announces-new-efficacy-analysis-comparing-brukinsa-r-vs-baaa0ejgx0p4.html

Stock_Titan Posted - 02/28/24

$BGNE BeiGene to Present at Upcoming Investor Conferences https://www.stocktitan.net/news/BGNE/bei-gene-to-present-at-upcoming-investor-hj6vx7h6op4s.html

SalmanAziz Posted - 02/27/24

$BGNE going to 200 bucks.

Pika_Capital Posted - 02/27/24

$bgne $zlab at least something today

briefingcom Posted - 02/27/24

$BGNE: BeiGene announces that the U.S. FDA has accepted a Biologics License Application for TEVIMBRA, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240227061001BGNE&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

Stock_Titan Posted - 02/27/24

$BGNE BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA https://www.stocktitan.net/news/BGNE/bei-gene-s-biologics-license-application-for-tevimbra-r-tislelizumab-3jvmbpo23pno.html

briefingcom Posted - 02/26/24

$BGNE: BeiGene beats by $0.08, reports revs in-line https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240226060856BGNE&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

epsguid Posted - 02/26/24

$BGNE reported a loss of $3.53, consensus was ($2.36) via @eWhispers #epsmiss http://eps.sh/d/bgne

DonCorleone77 Posted - 02/26/24

$BGNE BeiGene reports Q4 EPS ($3.53), consensus ($3.73) Reports Q4 revenue $634.4M, consensus $634.56M. "BeiGene made great progress in the fourth quarter and full year 2023 toward our goal to become an impactful next-generation oncology innovator. We have solidified our leadership in hematology with the continued success of BRUKINSA's global launch, led by U.S. and Europe," said John V. Oyler, Chairman, Co-Founder and CEO at BeiGene. "Our cost advantaged research and development and manufacturing have enabled us to build one of the largest and most exciting oncology pipelines in the industry. We look forward to a transformative year for BeiGene as we continue to deliver on operational excellence propelled by outstanding growth in revenue across new and existing geographies."